GENinCode: Funding, Investors & Team (Sep 2026)
GEN inCode specializes in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GEN inCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. Our products help inform patients of their health risk enabling them to make behavioral or ‘lifestyle’ changes whilst providing doctors with greater genetic insight and clinical information to determine the most effective treatment pathway (precision medicine). GEN inCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our molecular tests combine clinical algorithms and artificial intelligence to provide an advanced patient risk assessment to predict disease onset.
GENinCode has raised $700k across 1 funding round on record, the most recent a Private Equity of $700k announced in Aug 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GENinCode Company Profile and Key Stats
Latest funding round on record: Aug 2021.
GENinCode Funding Rounds
GENinCode Founders and Leadership Team
No contact details are on record for this team yet.
GENinCode Funding Compared to Other Biotechnology Startups
GENinCode's latest round of $700k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GENinCode in Biotechnology and Oxford
Companies Similar to GENinCode
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
GENinCode Funding FAQs
What does GENinCode do?
GEN inCode specializes in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GEN inCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. Our products help inform patients of their health risk enabling them to make behavioral or ‘lifestyle’ changes whilst providing doctors with greater genetic insight and clinical information to determine the most effective treatment pathway (precision medicine). GEN inCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our molecular tests combine clinical algorithms and artificial intelligence to provide an advanced patient risk assessment to predict disease onset.
How much funding has GENinCode raised?
GENinCode has raised $700k across 1 round on record. The most recent is a Private Equity of $700k announced in Aug 2021.
When did GENinCode last raise funding?
GENinCode's most recent funding round on record is a Private Equity of $700k, announced in Aug 2021.
Who is the CEO of GENinCode?
Matthew Walls is listed as CEO at GENinCode.
Where is GENinCode headquartered?
GENinCode is based in Oxford, Oxfordshire, United Kingdom.
How many employees does GENinCode have?
GENinCode is in the 11-50 employee band.
How does GENinCode's funding compare to other Biotechnology startups?
GENinCode's latest round of $700k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's GENinCode Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GENinCode is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.